Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

ooking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros' unproven preclinical and clinical development activities, regulatory oversight, commercialization of its products, intellectual property claims and the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.OMEROS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share data)Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012(unaudited)(unaudited)Revenue

$
96

$
,417

$
,431

$
4,439Operating expenses:Research and development

9,420

7,764

26,111

22,568Selling, general and administrative

4,210

2,736

11,934

7,270Litigation settlement

-

3,953

-

3,953Total operating expenses

13,630

14,453

38,045

33,791Loss from operations

(13,434)

(13,036)

(36,614)

(29,352)Investment income

2

14

10

32Interest expense

(592)

(413)

(1,768)

(1,360)Other income, (expense) net

154

159

421

(30)Net loss

$
(13,870)


SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... in PLoS Medicine , Susan Huang and colleagues ... tool, WHONET-SaTScan, made by integrating two freely available software ... software to microbiology data from patients admitted to a ... years (2002-2006), the authors found that the tool identified ...
... ... for fermenters is projected to reach $180 million by the year 2015. Growth in the ... disposable or single-use fermenters. , ... San Jose, California (PRWEB) February 22, 2010 -- Fermenters are witnessing sizeable growth in demand, ...
... in a special ink infused with nanoparticles, Stanford engineer ... efficiently manufacture lightweight paper batteries and supercapacitors (which, like ... means), as well as stretchable, conductive textiles known as ... mechanical properties of ordinary paper or fabric. While ...
Cached Biology Technology:Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 2Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 3Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 4US Fermenters Market to Reach $180 million by 2015, According to New Report by Global Industry Analysts, Inc. 2US Fermenters Market to Reach $180 million by 2015, According to New Report by Global Industry Analysts, Inc. 3Nanotechnology sparks energy storage on paper and cloth 2Nanotechnology sparks energy storage on paper and cloth 3
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... Polar Regions and the deep sea is the focus ... involving over 200 international scientists. The CAREX (Coordination ... roadmap outlines priorities for future research into life in ... Life has evolved thousands of strategies to adapt and ...
... nearly 390,000 chemical compounds had led scientists to a ... the brain with effects promising for new drugs for ... which blocks formation of cholesterol in the brain, in ... G. Kazantsev and colleagues previously discovered that blocking cholesterol ...
... lifted off on board India,s Polar Satellite Launch Vehicle ... on 20 April 2011. The X-SAT, developed ... collaboration with DSO National Laboratories, was launched from the ... India. The wholly made-in-Singapore satellite was one ...
Cached Biology News:Life in extreme environments paves the way for international collaboration 2Singapore's first locally made satellite launched into space 2